AACR 2019: Tarloxotinib promising against NRG1-fusion cancers

(University of Colorado Anschutz Medical Campus) University of Colorado Cancer Center study presented at AACR 2019 shows that the clinical-stage drug, tarloxotinib, is active against NRG1-fusion cancers, in addition to the HER2/EGFR cancers for which the drug was originally designed.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news